Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 3,530,000 shares, an increase of 28.4% from the January 31st total of 2,750,000 shares. Approximately 4.4% of the shares of the stock are short sold. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is presently 2.7 days.

Compass Therapeutics Trading Up 1.8 %

CMPX stock traded up $0.05 during trading on Tuesday, hitting $2.78. The company had a trading volume of 600,096 shares, compared to its average volume of 642,940. The business has a 50-day moving average of $2.64 and a 200-day moving average of $1.98. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The stock has a market cap of $382.50 million, a PE ratio of -7.51 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently modified their holdings of CMPX. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the third quarter worth approximately $25,000. Tower Research Capital LLC TRC raised its position in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after buying an additional 12,917 shares during the last quarter. Independent Advisor Alliance purchased a new stake in shares of Compass Therapeutics during the 4th quarter valued at $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics during the 4th quarter valued at $27,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $30,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CMPX has been the subject of a number of analyst reports. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, February 25th. Finally, Guggenheim started coverage on Compass Therapeutics in a report on Monday, February 24th. They set a “buy” rating and a $12.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.